Literature DB >> 20051519

Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Karen J Gregory1, Nathan E Hall, Andrew B Tobin, Patrick M Sexton, Arthur Christopoulos.   

Abstract

Muscarinic acetylcholine receptors contain at least one allosteric site that is topographically distinct from the acetylcholine, orthosteric binding site. Although studies have investigated the basis of allosteric modulation at these receptors, less is known about putative allosteric ligands that activate the receptor in their own right. We generated M(2) muscarinic acetylcholine receptor mutations in either the orthosteric site in transmembrane helices 3 and 6 (TM3 and -6) or part of an allosteric site involving the top of TM2, the second extracellular (E2) loop, and the top of TM7 and investigated their effects on the binding and function of the novel selective (putative allosteric) agonists (AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl), 77-LH-28-1 (1-(3-(4-butyl-1-piperidinyl)propyl)-3,3-dihydro-2(1H)-quinolinone), and N-desmethylclozapine) as well as the bitopic orthosteric/allosteric ligand, McN-A-343 (4-(m-chlorophenyl-carbamoyloxy)-2-butynyltrimethylammonium). Four classes of agonists were identified, depending on their response to the mutations, suggesting multiple, distinct modes of agonist-receptor interaction. Interestingly, with the exception of 77-LH-28-1, allosteric site mutations had no effect on the affinity of any of the agonists tested, but some mutations in the E2 loop influenced the efficacy of both orthosteric and novel selective agonists, highlighting a role for this region of the receptor in modulating activation status. Two point mutations (Y104(3.33)A (Ballesteros and Weinstein numbers in superscript) in the orthosteric and Y177A in the allosteric site) unmasked ligand-selective and signaling pathway-selective effects, providing evidence for the existence of pathway-specific receptor conformations. Molecular modeling of 77-LH-28-1 and N-desmethylclozapine yielded novel binding poses consistent with the possibility that the functional selectivity of such agents may arise from a bitopic mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20051519      PMCID: PMC2844194          DOI: 10.1074/jbc.M109.094011

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  76 in total

1.  Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.

Authors:  J A Javitch; D Fu; G Liapakis; J Chen
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

2.  Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.

Authors:  Vimesh Avlani; Lauren T May; Patrick M Sexton; Arthur Christopoulos
Journal:  J Pharmacol Exp Ther       Date:  2004-01-07       Impact factor: 4.030

3.  Pronounced conformational changes following agonist activation of the M(3) muscarinic acetylcholine receptor.

Authors:  Sung-Jun Han; Fadi F Hamdan; Soo-Kyung Kim; Kenneth A Jacobson; Lars Brichta; Lanh M Bloodworth; Jian H Li; Jürgen Wess
Journal:  J Biol Chem       Date:  2005-05-02       Impact factor: 5.157

4.  Multiple residues in the second extracellular loop are critical for M3 muscarinic acetylcholine receptor activation.

Authors:  Marco Scarselli; Bo Li; Soo-Kyung Kim; Jürgen Wess
Journal:  J Biol Chem       Date:  2007-01-09       Impact factor: 5.157

5.  Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands.

Authors:  Stefan Buller; Darius Paul Zlotos; Klaus Mohr; John Ellis
Journal:  Mol Pharmacol       Date:  2002-01       Impact factor: 4.436

6.  Identification of a ligand-dependent switch within a muscarinic receptor.

Authors:  T A Spalding; E S Burstein; S C Henderson; K R Ducote; M R Brann
Journal:  J Biol Chem       Date:  1998-08-21       Impact factor: 5.157

7.  Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors.

Authors:  A L Gnagey; M Seidenberg; J Ellis
Journal:  Mol Pharmacol       Date:  1999-12       Impact factor: 4.436

Review 8.  Muscarinic acetylcholine receptors: signal transduction through multiple effectors.

Authors:  C C Felder
Journal:  FASEB J       Date:  1995-05       Impact factor: 5.191

Review 9.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

10.  Activation of solubilized G-proteins by muscarinic acetylcholine receptors.

Authors:  G Hilf; K H Jakobs
Journal:  Cell Signal       Date:  1992-11       Impact factor: 4.315

View more
  54 in total

1.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

2.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Emilia E Savage; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

3.  Depolarization induces a conformational change in the binding site region of the M2 muscarinic receptor.

Authors:  Noa Dekel; Michael F Priest; Hanna Parnas; Itzchak Parnas; Francisco Bezanilla
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-19       Impact factor: 11.205

4.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

5.  Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.

Authors:  Vindhya Nawaratne; Katie Leach; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-04-20       Impact factor: 5.157

6.  Human Neuropeptide S Receptor Is Activated via a Gαq Protein-biased Signaling Cascade by a Human Neuropeptide S Analog Lacking the C-terminal 10 Residues.

Authors:  Yuan Liao; Bin Lu; Qiang Ma; Gang Wu; Xiangru Lai; Jiashu Zang; Ying Shi; Dongxiang Liu; Feng Han; Naiming Zhou
Journal:  J Biol Chem       Date:  2016-02-10       Impact factor: 5.157

7.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design.

Authors:  A J Kooistra; S Kuhne; I J P de Esch; R Leurs; C de Graaf
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

8.  Muscarinic receptors as model targets and antitargets for structure-based ligand discovery.

Authors:  Andrew C Kruse; Dahlia R Weiss; Mario Rossi; Jianxin Hu; Kelly Hu; Katrin Eitel; Peter Gmeiner; Jürgen Wess; Brian K Kobilka; Brian K Shoichet
Journal:  Mol Pharmacol       Date:  2013-07-25       Impact factor: 4.436

9.  Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.

Authors:  Frederick J Ehlert; Michael T Griffin
Journal:  J Pharmacol Toxicol Methods       Date:  2014-01-13       Impact factor: 1.950

Review 10.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.